Human Milk Pasteurization via UV Vortical Flow
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pasteurization methods for human milk, such as thermal pasteurization, fail to effectively inactivate biological contaminants while preserving the bioactive components essential for infant health, leading to reduced milk quality and potential disease transmission risks.
Innovation Solution
Exposure of human milk to ultraviolet light (UV) with a wavelength of 250-270 nm, combined with a vortical flow, to inactivate biological contaminants without significantly reducing the activity of bioactive components like lactoferrin, lysozyme, and secretory IgA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thermal pasteurization is used to inactivate biological contaminants, then microbial reduction is achieved, but bioactive components are altered or lost
Solution Approach 1:
The patent replaces the thermal pasteurization system with a UV irradiation system. Instead of using heat (thermal energy) to inactivate contaminants, the invention uses ultraviolet light (electromagnetic radiation) to achieve the same microbial inactivation effect while avoiding thermal damage to bioactive components. This substitution of the physical mechanism resolves the contradiction between effective pathogen reduction and preservation of heat-sensitive nutrients.
Solution Approach 2:
The patent changes the parameter of energy type from thermal energy to electromagnetic energy (UV radiation). By using UV light at specific wavelengths (200-280 nm, particularly 254 nm) instead of heat, the process achieves microbial inactivation through a different physical parameter that does not cause thermal degradation of bioactive components, thus resolving the contradiction between contaminant reduction and nutrient preservation.
2Reliability
If UV treatment is applied to opaque liquids, then microbial reduction is achieved, but light penetration is limited due to high absorption coefficient
Solution Approach 1:
The patent segments the UV irradiation process by using multiple UV lamps positioned at different locations around the container, ensuring that light reaches the milk from multiple directions. This segmentation of the illumination source compensates for the high absorption coefficient of milk by providing cumulative UV exposure from various angles, thereby achieving effective microbial inactivation despite the opaque nature of the liquid.
Solution Approach 2:
The patent transitions from single-directional UV irradiation to multi-directional irradiation by positioning UV lamps around the container. This adds spatial dimensions to the light exposure, allowing UV photons to reach contaminants throughout the milk volume by traveling through different paths, thereby overcoming the limitation of light penetration in opaque liquids.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively reduces microbial loads in human milk by at least 5 Log10 units while maintaining the bioactive properties, resulting in a higher-quality pasteurized milk product that is safer for infants and immune-incompetent adults.
Implementation Method 1
exposing the human milk product to ultraviolet light (UV) having a wavelength from 250 nm to 270 nm
Implementation Method 2
imparting a vortical flow to the human milk product to facilitate exposure of the biological contaminant in the milk product to the UV light
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention relates to a method and apparatus for the inactivation of a biological contaminant in a human milk product by exposing the milk product to UV by imparting a vortical flow to the milk product. The exposure inactivates or reduces the amount of a contaminant in the milk product; and the activity of a bioactive component present in the milk product is not substantially reduced. The contaminant may be selected from a group comprising E. coli, Staphylococcus spp. Streptococcus spp., Bacillus spp., Enterococcus spp. and Enterobacter spp., Cytomegalovirus, Human immunodeficiency virus or Human T- lymphotrophic virus. The bioactive component may be a carbohydrate, lipid, protein, fatty acid, enzyme, antibody, growth factor, cytokine, chemokine, hormone, antimicrobial compound or metabolite